Updated just now · Live
Stock analysis, price data, and AI-powered insights for MeiraGTx Holdings PLC (MGTX).
MeiraGTx Holdings PLC operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for MGTX.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). MGTX Stock Intelligence Report. [stoxpulse.com/stocks/mgtx]
Disclaimer: The information on this page about MeiraGTx Holdings PLC (MGTX) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for MeiraGTx Holdings PLC.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
MEIRAGTX HOLDINGS PLC : COMPANY ANNOUNCEMENT
1d ago
RBC Capital Maintains Outperform on MeiraGTx Holdi...
4d ago
StoxPulse AI results for MGTX: Pulse Score 48/100. Primary sentiment trends from 14 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$857.6M
P/E Ratio
—
EPS
$-0.62
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
MEIRAGTX HOLDINGS PLC : COMPANY ANNOUNCEMENT
RBC Capital Maintains Outperform on MeiraGTx Holdings, Raises Price Target to $24
MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity Transcript
12 Health Care Stocks Moving In Thursday's Intraday Session
Transcript : MeiraGTx Holdings plc - Special Call
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson
MeiraGTx : AQP1 3 year data presentation 4162026
MeiraGTx Holdings shares are trading lower after the company announced the pricing of its $100 million offering of 11,111,111 shares at $9 per share. Also, the company entered into an asset purchase agreement with Johnson & Johnson to acquire all interests in bota-vec for the treatment of XLRP.